Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDRigel Pharmaceuticals Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 2 | $0.57 | $1.02 | $0.80 |
| Q2 2026 | 3 | $0.07 | $0.11 | $0.09 |
| Q3 2026 | 3 | $0.78 | $1.00 | $0.89 |
| Q4 2026 | 3 | $0.92 | $1.10 | $1.02 |
| Q1 2027 | 1 | $0.63 | $0.69 | $0.66 |
| Q2 2027 | 1 | $0.88 | $0.96 | $0.92 |
| Q3 2027 | 1 | $0.98 | $1.06 | $1.02 |
| Q4 2027 | 1 | $1.15 | $1.24 | $1.20 |
Rigel Pharmaceuticals Earnings Date And Information
Rigel Pharmaceuticals last posted its earnings results on Tuesday, August 4th, 2026. The company reported $0.88 earnings per share for the quarter, topping analysts' consensus estimates of $0.08766 by $0.79234. The company had revenue of 78.70 M for the quarter and had revenue of 294.28 M for the year. Rigel Pharmaceuticals has generated $20 earnings per share over the last year ($19.48 diluted earnings per share) and currently has a price-to-earnings ratio of 2.29. Rigel Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Rigel Pharmaceuticals Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/04/2026 | Q2 2026 | $0.09 | $0.93 | 0.84 | $55.27 M | $78.70 M |
| 05/05/2026 | Q1 2026 | $0.74 | $0.47 | -0.27 | $62.40 M | $58.82 M |
| 03/03/2026 | Q4 2025 | $1.33 | $14.72 | 13.39 | $68.70 M | $69.80 M |
| 11/04/2025 | Q3 2025 | $0.93 | $1.55 | 0.62 | $61.88 M | $69.46 M |
| 08/05/2025 | Q2 2025 | $1.97 | $3.33 | 1.36 | $88.95 M | $101.69 M |
| 05/06/2025 | Q1 2025 | $0.14 | $0.64 | 0.5 | $43.87 M | $53.33 M |
| 03/04/2025 | Q4 2024 | $0.30 | $0.81 | 0.51 | $50.10 M | $57.60 M |
| 11/07/2024 | Q3 2024 | $0.06 | $0.71 | 0.65 | $41.94 M | $55.31 M |
| 08/06/2024 | Q2 2024 | -$0.37 | -$0.06 | 0.31 | $33.42 M | $36.84 M |
| 05/07/2024 | Q1 2024 | -$0.30 | -$0.47 | -0.17 | $31.47 M | $29.53 M |
| 03/05/2024 | Q4 2023 | $0.02 | $0.04 | 0.02 | $34.10 M | $35.79 M |
| 11/07/2023 | Q3 2023 | -$0.70 | -$0.33 | 0.37 | $27.20 M | $28.13 M |
| 08/01/2023 | Q2 2023 | -$0.80 | -$0.38 | 0.42 | $25.70 M | $26.89 M |
| 05/02/2023 | Q1 2023 | -$0.90 | -$0.80 | 0.1 | $24.07 M | $26.07 M |
| 03/07/2023 | Q4 2022 | -$0.70 | $0.10 | 0.8 | $36.52 M | $51.28 M |
| 11/03/2022 | Q3 2022 | -$1.30 | -$1.10 | 0.2 | $22.61 M | $22.41 M |
| 08/02/2022 | Q2 2022 | -$1.20 | -$0.80 | 0.4 | $23.65 M | $29.82 M |
| 05/03/2022 | Q1 2022 | -$1.20 | -$1.60 | -0.4 | $17.58 M | $16.74 M |
| 03/01/2022 | Q4 2021 | -$1.30 | -$1.30 | 0 | $21.90 M | $20.41 M |
| 11/02/2021 | Q3 2021 | -$1.00 | -$1.20 | -0.2 | $23.56 M | $21.54 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Rigel Pharmaceuticals Earnings: FAQ's
In the previous quarter, Rigel Pharmaceuticals (:RIGL) reported $0.88 earnings per share (EPS) to beat the analysts' consensus estimate of $0.08766 by $0.79234.
The conference call for Rigel Pharmaceuticals's latest earnings report can be listened to online.
The conference call transcript for Rigel Pharmaceuticals's latest earnings report can be read online.
Rigel Pharmaceuticals (:RIGL) has a recorded annual revenue of $294.28 M.
Rigel Pharmaceuticals (:RIGL) has a recorded net income of $367.02 M.Rigel Pharmaceuticals has generated $20.4 earnings per share over the last four quarters.
Rigel Pharmaceuticals (:RIGL) has a price-to-earnings ratio of 2.29 and price/earnings-to-growth ratio is 0.01.